We aim to develop better treatments that can make a real impact in people’s lives.

$MBRX #STSLungMets #Sarcoma #AcuteMyeloidLeukemia #Oncology

September 6, 2022: Received FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme.

bit.ly/3UEo9vJ
$MBRX #STSLungMets #Sarcoma #AcuteMyeloidLeukemia #Oncology

September 27, 2022: WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral.

bit.ly/3FW4LGB
$MBRX #STSLungMets #Sarcoma #AcuteMyeloidLeukemia #Oncology

October 14, 2022: Provided Update on Second Multiple Ascending Dose Cohort in Phase 1a Clinical Trial of WP1122 in the UK.

bit.ly/3DR4yBQ
$MBRX #STSLungMets #Sarcoma #AcuteMyeloidLeukemia #Oncology

We are advancing a growing pipeline for the treatment of highly resistant cancers and viruses.

Learn more here: bit.ly/3LyysMR
$MBRX #STSLungMets #Sarcoma #AcuteMyeloidLeukemia #Oncology

Learn why we are a Company to watch for 2023.

$MBRX #STSLungMets #Sarcoma #AcuteMyeloidLeukemia #Oncology